The first commercial offers will be available in the coming months. They will provide unprecedented solutions to current techniques in terms of assessment of toxicity and efficacy of new drugs and cosmetic products.
iPS cell technologies enable adult cells, from sources such as skin or hair, to be reprogrammed to behave like stem cells, which have the capacity to give rise to any cell type such as the heart or liver. Their development should help structure the health and cosmetic industrial sectors. There are numerous potential applications of iPS technologies, in both the therapeutic and industrial sectors, and they address very large markets, due to the fact that they can overcome the volume limitations of the current technologies.
This agreement with Caisse des Depots strengthens Cellectis commitment in the stem cell domain, following on from the collaborative StemRed project, conducted in partnership with Etablissement Francais du Sang (French Blood Agency), with the purpose of producing red blood cells from iPS cells as announced on March 8, 2011.
A subsidiary of Cellectis founded in August 2009, Ectycell is dedicated to the development, production and marketing of tools for generating induced pluripotent stem cells from adult cells for industrial and therapeutic applications.
Cellectis improves life by applying its genome engineering expertise to a broad range of applications, including human therapeutics, bioresearch and agriculture. Cellectis is listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris. More information at www.cellectis.com.
Follow Cellectis on Twitter at www.twitter.com/cellectis.
About Caisse des Depots
Caisse des Depots and its affili
Copyright©2010 PR Newswire.
All rights reserved